Interactions between alcohol and the HIV entry inhibitor maraviroc

Journal of the International Association of Providers of AIDS Care

Volumn 12, Issue 6, 2013, Pages 375-377

  Gruber, Valerie A ^a   Rainey, Petrie M ^b   Lum, Paula J ^c   Beatty, George W ^c   Aweeka, Francesca T ^a   McCance Katz, Elinore F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

alcohol; drug interactions; HIV AIDS; maraviroc

Indexed keywords

ALCOHOL; INDINAVIR; MARAVIROC; PLACEBO; RIBOFLAVIN;

ALCOHOL CONSUMPTION; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFECT; FEMALE; FOOD DRUG INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MALE; MAXIMUM PLASMA CONCENTRATION; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION; VIRUS LOAD;

EID: 84887947220     PISSN: 23259574     EISSN: 23259582     Source Type: Journal    
DOI: 10.1177/2325957413495567     Document Type: Article

References (10)

1. Chander G, Lau B, Moore RD. Hazardous alcohol use: a risk factor for non-adherence and lack of suppression in HIV infection. J Acquir Immune Defic Syndr. 2006 ; 43 (4). 411-417
2. Kalichman SC, Grebler T, Amaral CM, et al. Intentional non-adherence to medications among HIV positive alcohol drinkers: prospective study of interactive toxicity beliefs. J Gen Intern Med. 2013 ; 28 (3). 399-405
3. Bangsberg DR. Preventing HIV antiretroviral resistance through better monitoring of treatment adherence. J Infect Dis. 2008 ; 197 (suppl 3). S272 - S278
4. Lieberman-Blum SS, Fung HB, Bandres JC. Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection. Clin Ther. 2008 ; 30 (7). 1228-1250
5. Hyland R, Dickins M, Collins C, Jones H, Jones B. Maraviroc: in vitro assessment of drug-drug interaction potential. Br J Clin Pharmacol. 2008 ; 66 (4). 498-507
6. Lieber CS. The discovery of the microsomal ethanol oxidizing system and its physiologic and pathologic role. Drug Metab Rev. 2004 ; 36 (3-4). 511-529
7. McCance-Katz EF, Moody DE, Morse GD, et al. Interactions between buprenorphine and antiretrovirals I: nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine. Clin Infect Dis. 2006 ; 43 (supp 4). S224 - S234
8. Torsten E, Bosron WF, Li TK. Alcohol and aldehyde dehydrogenase. Alcohol Alcohol. 1990 ; 25 (2-3). 105-116
9. McCance-Katz EF, Lum PJ, Beatty G, Gruber VA, Peters M, Rainey PM. Untreated HIV infection is associated with higher blood alcohol levels. J Acquir Immune Defic Syndr. 2012 ; 60 (3). 282-288
10. Epple HJ, Schneider T, Troeger H, et al. Impairment of the intestinal barrier is evident in untreated but absent in suppressively treated HIV infected patients. Gut. 2009 ; 58 (2). 220-227